Aureus Asset Management LLC Sells 6,555 Shares of Ultragenyx Pharmaceutical Inc. (RARE)

Aureus Asset Management LLC cut its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 10.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 59,115 shares of the biopharmaceutical company’s stock after selling 6,555 shares during the period. Aureus Asset Management LLC owned approximately 0.14% of Ultragenyx Pharmaceutical worth $3,148,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in RARE. Cubist Systematic Strategies LLC lifted its position in shares of Ultragenyx Pharmaceutical by 83.7% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 5,570 shares of the biopharmaceutical company’s stock valued at $346,000 after acquiring an additional 2,538 shares in the last quarter. State of Wisconsin Investment Board purchased a new stake in shares of Ultragenyx Pharmaceutical in the 2nd quarter valued at approximately $1,739,000. Russell Investments Group Ltd. lifted its position in shares of Ultragenyx Pharmaceutical by 11.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 31,184 shares of the biopharmaceutical company’s stock valued at $1,937,000 after acquiring an additional 3,195 shares in the last quarter. AXA lifted its position in shares of Ultragenyx Pharmaceutical by 42.8% in the 2nd quarter. AXA now owns 236,653 shares of the biopharmaceutical company’s stock valued at $14,699,000 after acquiring an additional 70,968 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Ultragenyx Pharmaceutical by 7.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 30,864 shares of the biopharmaceutical company’s stock valued at $1,917,000 after acquiring an additional 2,212 shares in the last quarter. 94.13% of the stock is owned by institutional investors and hedge funds.

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ RARE) opened at $51.76 on Tuesday. Ultragenyx Pharmaceutical Inc. has a 12-month low of $44.02 and a 12-month high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($1.87). The company had revenue of $0.20 million during the quarter, compared to analysts’ expectations of $0.02 million. During the same quarter in the previous year, the company earned ($1.64) EPS. The firm’s quarterly revenue was up 81.8% compared to the same quarter last year. equities analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -7.26 earnings per share for the current fiscal year.

RARE has been the subject of several research analyst reports. Canaccord Genuity restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, September 12th. Stifel Nicolaus restated a “buy” rating and issued a $85.00 price target (down previously from $95.00) on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, August 23rd. J P Morgan Chase & Co set a $76.00 price target on shares of Ultragenyx Pharmaceutical and gave the company a “buy” rating in a research report on Wednesday, August 23rd. Robert W. Baird restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, September 19th. Finally, Cowen restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 15th. Ten investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Ultragenyx Pharmaceutical has an average rating of “Hold” and an average price target of $72.27.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/12/05/aureus-asset-management-llc-sells-6555-shares-of-ultragenyx-pharmaceutical-inc-rare.html.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE).

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply